6,183 results on '"Cardiomyopathies physiopathology"'
Search Results
2. Cardiopulmonary exercise testing in transthyretin amyloid cardiomyopathy patients: a long-term follow-up study.
- Author
-
Willixhofer R, Rettl R, Kronberger C, Ermolaev N, Gregshammer B, Duca F, Binder C, Kammerlander A, Alasti F, Kastner J, Bonderman D, Bergler-Klein J, Agostoni P, and Badr Eslam R
- Subjects
- Humans, Male, Female, Aged, Follow-Up Studies, Aged, 80 and over, Time Factors, Predictive Value of Tests, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial physiopathology, Amyloid Neuropathies, Familial blood, Amyloid Neuropathies, Familial therapy, Exercise Test methods, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis, Cardiomyopathies etiology, Cardiomyopathies blood, Exercise Tolerance, Oxygen Consumption
- Abstract
Aims: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) experience reduced functional capacity. We evaluated changes in functional capacity over extensive follow-up using cardiopulmonary exercise testing (CPX)., Methods: ATTR-CM patients underwent CPX and blood testing at baseline, first [V1, 8 (6-10) months] and second follow-up (V2) at 35 (26-41) months after start of disease-specific therapy., Results: We included 34 ATTR-CM patients, aged 77 (±6) years (88.2% men). CPX showed two patterns with functional capacity improvement at V1 and deterioration at V2. Peak work capacity ( P = 0.005) and peak oxygen consumption (VO 2 , P = 0.012) increased at V1 compared with baseline and decreased at V2. The ventilation to carbon dioxide relationship slope (VE/VCO 2 ) increased at V2 compared with baseline and V1 ( P = 0.044). A cut-off for peak VO 2 at 14 ml/kg·min showed more events (composite of death and heart failure hospitalization): less than 14 vs. greater than 14 ml/kg·min ( P = 0.013). Cut-offs for VE/VCO 2 slope at 40 showed more events greater than 40 vs. less than 40 ( P = 0.009)., Conclusion: ATTR-CM patients showed an improvement and deterioration in the short-term and long-term follow-up, respectively, with a better prognosis for those with peak VO 2 above 14 ml/kg·min and for a VE/VCO 2 slope below 40., (Copyright © 2024 Italian Federation of Cardiology - I.F.C. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Nexilin in cardiomyopathy: unveiling its diverse roles with special focus on endocardial fibroelastosis.
- Author
-
Rahimzadeh M, Tennstedt S, and Aherrahrou Z
- Subjects
- Humans, Microfilament Proteins genetics, Microfilament Proteins metabolism, Phenotype, Cardiomyopathies genetics, Cardiomyopathies diagnosis, Cardiomyopathies physiopathology, Cardiomyopathies metabolism, Endocardial Fibroelastosis genetics, Endocardial Fibroelastosis metabolism, Endocardial Fibroelastosis diagnosis, Mutation
- Abstract
Cardiac disorders exhibit considerable heterogeneity, and understanding their genetic foundations is crucial for their diagnosis and treatment. Recent genetic analyses involving a growing number of participants have uncovered novel mutations within both coding and non-coding regions of DNA, contributing to the onset of cardiac conditions. The NEXN gene, encoding the Nexilin protein, an actin filament-binding protein, is integral to normal cardiac function. Mutations in this gene have been linked to cardiomyopathies, cardiovascular disorders, and sudden deaths. Heterozygous or homozygous variants of the NEXN gene are associated with the development of endocardial fibroelastosis (EFE), a rare cardiac condition characterized by excessive collagen and elastin deposition in the left ventricular endocardium predominantly affecting infants and young children. EFE occurs both primary and secondary to other conditions and often leads to unfavorable prognoses and outcomes. This review explores the role of NEXN genetic variants in cardiovascular disorders, particularly EFE, revealing that functional mutations are not clustered in a specific domain of Nexilin based on the cardiac disorder phenotype. Our review underscores the importance of understanding genetic mutations for the diagnosis and treatment of cardiac conditions., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
4. Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype.
- Author
-
Singulane C, Sun D, Hu Z, Lee L, Sarswat N, Emami Neyestanak M, Patel AR, Lang RM, and Addetia K
- Subjects
- Humans, Male, Female, Aged, Prognosis, Echocardiography methods, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial physiopathology, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial mortality, Retrospective Studies, Middle Aged, Aged, 80 and over, Risk Factors, Predictive Value of Tests, Ventricular Function, Left physiology, Amyloidosis diagnosis, Amyloidosis physiopathology, Amyloidosis diagnostic imaging, Heart Ventricles diagnostic imaging, Heart Ventricles physiopathology, Survival Rate trends, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis, Cardiomyopathies diagnostic imaging, Immunoglobulin Light-chain Amyloidosis diagnosis, Immunoglobulin Light-chain Amyloidosis physiopathology, Immunoglobulin Light-chain Amyloidosis diagnostic imaging, Immunoglobulin Light-chain Amyloidosis mortality
- Abstract
Background: Current echocardiographic risk factors for prognosis in cardiac amyloidosis (CA) do not distinguish between the two main subtypes: transthyretin cardiomyopathy (TTR) and immunoglobulin light chain cardiomyopathy (AL), each of which require distinct diagnostic and therapeutic approaches. Additionally, only traditional parameters have been studied with little data on advanced techniques. Accordingly, we sought to determine whether differences exist in 2D transthoracic echocardiography (2DE) predictors of survival between the CA subtypes using a comprehensive approach., Methods: 220 patients (72±12 years) with confirmed CA (AL=89, TTR=131) who underwent 2DE at the time of CA diagnosis were enrolled. Left ventricular (LV) dimensions, indexed mass (LVMi), global longitudinal strain (LVGLS), apical-sparing ratio (LVASR), diastology, right ventricular (RV) size and function indices including tricuspid annular systolic excursion (TAPSE), RV free-wall (RVFWS) and global (RVGLS) strain, indexed left (LA) and right atrial volumes (LAVi and RAVi), LA strain (reservoir and booster) and RV systolic pressure (RVSP) were measured. A propensity-score weighted stepwise variable selection Cox proportional hazards model derived from NYHA class and renal impairment status at diagnosis was used to determine the associations between 2DE parameters and mortality specific to CA subtype over a median follow-up of 36-months., Results: After adjusting for age, atrial fibrillation and treatment, parameters associated with survival were RVFWS (p=0.003, HR 1.15, 95% CI[1.053,1.245]) and RVSP (p=0.03, HR 1.03, 95% CI[1.004,1.063]) in AL and LVASR (p=0.007, HR 6.68, 95% CI[1.75,25.492]) and RAVi (p=0.049, HR 1.03, 95% CI[1.000,1.052]) in TTR., Conclusions: Echocardiographic prognosticators for survival are specific to cardiac amyloid subtype. These results potentially provide information critical for clinical decision-making and follow-up in these patients., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Karima Addetia reports financial support was provided by Pfizer Inc. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. The differentiation of the competitive athlete with physiologic cardiac remodeling from the athlete with cardiomyopathy.
- Author
-
Henning RJ
- Subjects
- Humans, Diagnosis, Differential, Cardiomegaly, Exercise-Induced physiology, Echocardiography methods, Athletes, Ventricular Remodeling physiology, Electrocardiography, Cardiomyopathies diagnosis, Cardiomyopathies physiopathology
- Abstract
There are currently 5 million active high school, collegiate, professional, and master athletes in the United States. Regular intense exercise by these athletes can promote structural, electrical and functional remodeling of the heart, which is termed the "athlete's heart." In addition, regular intense exercise can lead to pathological adaptions that promote or worsen cardiac disease. Many of the athletes in the United States seek medical care. Consequently, physicians must be aware of the normal cardiac anatomy and physiology of the athlete, the differentiation of the normal athlete heart from the athlete with cardiomyopathy, and the contemporary care of the athlete with a cardiomyopathy. In athletes with persistent cardiovascular symptoms, investigations should include a detailed history and physical examination, an ECG, a transthoracic echocardiogram, and in athletes in whom the diagnosis is uncertain, a maximal exercise stress test or a continuous ECG recording, and cardiac magnetic resonance imaging or cardiac computed tomography angiography when definition of the coronary anatomy or characterization of the aorta and the aortic great vessels is indicated. This article discusses the differentiation of the normal athlete with physiologic cardiac remodeling from the athlete with hypertrophic, dilated or arrhythmogenic ventricular cardiomyopathy (ACM). The ECG changes in trained athletes that are considered normal, borderline, or abnormal are listed. In addition, the normal echocardiographic measurements for athletes who consistently participate in endurance, power, combined or heterogeneous sports are enumerated and discussed. Algorithms are listed that are useful in the diagnosis of trained athletes with borderline or abnormal echocardiographic measurements suggestive of cardiomyopathies along with the major and minor criteria for the diagnosis of ACM in athletes. Thereafter, the treatment of athletes with hypertrophic, dilated, and arrhythmogenic right ventricular cardiomyopathies are reviewed. The distinction between physiologic changes and pathologic changes in the hearts of athletes has important therapeutic and prognostic implications. Failure by the physician to correctly diagnose an athlete with hypertrophic cardiomyopathy, dilated cardiomyopathy, or ACM, can lead to the sudden cardiac arrest and death of the athlete during training or sports competition. Conversely, an incorrect diagnosis by a physician of cardiac pathology in a normal athlete can lead to an unnecessary restriction of athlete training and competition with resultant significant emotional, psychological, financial, and long-term health consequences in the athlete., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
6. Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy.
- Author
-
Uemura K, Ichikawa Y, Nagai S, Nishihara Y, Todo S, Oota E, Odajima S, Takeuchi K, Kintsu M, Fukuda T, Hisamatsu E, Hirata KI, and Tanaka H
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Echocardiography, Prealbumin genetics, Prealbumin metabolism, Treatment Outcome, Aged, 80 and over, Benzoxazoles therapeutic use, Amyloid Neuropathies, Familial physiopathology, Amyloid Neuropathies, Familial drug therapy, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial complications, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis, Cardiomyopathies drug therapy, Atrial Function, Left drug effects, Atrial Function, Left physiology, Heart Atria physiopathology, Heart Atria diagnostic imaging, Heart Atria drug effects
- Abstract
Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the functional and structural effects of amyloid infiltration, predominantly within the ventricles, causing biventricular wall thickening. Amyloid infiltration can be observed in the left atrium in ATTR-CM patients, but the association of left atrial (LA) myocardial function with cardiovascular events and of changes in LA myocardial function with tafamidis administration have not yet been clarified. Our aim was, therefore, to use speckle-tracking strain for investigating LA myocardial function in patients with ATTR-CM treated with tafamidis. We studied 55 patients with biopsy-proven ATTR-CM who had been treated with tafamidis (age: 76 ± 2 years, male: 93%). For speckle-tracking analysis of LA myocardial function, the systolic LA strain (LA reservoir function) was defined for this study as LA myocardial function from the apical 4-chamber view. The primary endpoint was defined as a composite comprising cardiovascular death and/or heart failure hospitalization after tafamidis administration over a median follow-up period of 28 ± 4 months. Patients with baseline LA strain < 8.6% (median value) experienced significantly more cardiovascular events than those without (log-rank P = 0.002). Moreover, LA strain in 26 patients worsened after tafamidis administration, and multivariate logistic regression analysis showed age, global longitudinal strain and relative apical longitudinal strain index were identified as independent determinants of deterioration of LA strain after tafamidis administration. In conclusion, baseline LA reservoir function is closely associated with cardiovascular events after tafamidis administration, and could be an additional parameter for the management of patients with ATTR-CM., (© 2024. Springer Nature Japan KK, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
7. Incident stroke in individuals with peripartum cardiomyopathy.
- Author
-
Ibeh C, Kulick ER, Boehme AK, Friedman AM, Miller EC, and Bello NA
- Subjects
- Humans, Female, Pregnancy, Incidence, Adult, Stroke Volume physiology, Risk Factors, Heart Failure epidemiology, Heart Failure etiology, Puerperal Disorders epidemiology, Puerperal Disorders etiology, Retrospective Studies, Stroke epidemiology, Stroke etiology, Pregnancy Complications, Cardiovascular epidemiology, Peripartum Period, Cardiomyopathies epidemiology, Cardiomyopathies physiopathology
- Abstract
Background: Peripartum cardiomyopathy (PPCM), a form of heart failure with reduced ejection fraction (HFrEF) that occurs during the final month of pregnancy through the first 5 months postpartum, is associated with heightened risk for maternal morbidity and mortality. Stroke is a common complication of HFrEF but there is limited data on the incidence of stroke in PPCM., Methods: Using statewide, nonfederal administrative data from 2000 to 2015, we analyzed age-adjusted risk of stroke within 3 years after PPCM-associated pregnancies., Results: PPCM was associated with a greater than 4-fold increased risk of pregnancy-related stroke (aHR 4.7, 95% CI: 3.0-7.5). This risk was highest at the time of PPCM diagnosis but remained elevated in the first postpartum year., Conclusion: Our findings confirm the strong association between PPCM and stroke, with risk that persists throughout and after the peripartum period., Competing Interests: Conflict of interest The authors have nothing to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. New insights gained from cellular landscape changes in myocarditis and inflammatory cardiomyopathy.
- Author
-
Wang W, Jia H, Hua X, and Song J
- Subjects
- Humans, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Myocardium pathology, Myocardium metabolism, Single-Cell Analysis methods, Myocarditis physiopathology, Myocarditis metabolism, Cardiomyopathies etiology, Cardiomyopathies physiopathology
- Abstract
Advances in the etiological classification of myocarditis and inflammatory cardiomyopathy (ICM) have reached a consensus. However, the mechanism of myocarditis/ICM remains unclear, which affects the development of treatment and the improvement of outcome. Cellular transcription and metabolic reprogramming, and the interactions between cardiomyocytes and non-cardiomyocytes, such as the immune cells, contribute to the process of myocarditis/ICM. Recent efforts have been made by multi-omics techniques, particularly in single-cell RNA sequencing, to gain a better understanding of the cellular landscape alteration occurring in disease during the progression. This article aims to provide a comprehensive overview of the latest studies in myocarditis/ICM, particularly as revealed by single-cell sequencing., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
9. Navigating the penetrance and phenotypic spectrum of inherited cardiomyopathies.
- Author
-
Serpa F, Finn CM, and Tahir UA
- Subjects
- Humans, Genetic Predisposition to Disease, Death, Sudden, Cardiac etiology, Death, Sudden, Cardiac prevention & control, Risk Assessment methods, Mutation, Penetrance, Cardiomyopathies genetics, Cardiomyopathies physiopathology, Phenotype, Genetic Testing methods
- Abstract
Inherited cardiomyopathies are genetic diseases that can lead to heart failure and sudden cardiac death. These conditions tend to run in families, following an autosomal dominant pattern where first-degree relatives have a 50% chance of carrying the pathogenic variant. Despite significant advancements and increased accessibility of genetic testing, accurately predicting the phenotypic expression of these conditions remains challenging due to the inherent variability in their clinical manifestations and the incomplete penetrance observed. This poses challenges in providing patient care and effectively communicating the potential risk of future disease to patients and their families. To address these challenges, this review aims to synthesize the available evidence on penetrance, expressivity, and factors influencing disease expression to improve communication and risk assessment for patients with inherited cardiomyopathies and their family members., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
10. Genetic and Pathophysiological Basis of Cardiac and Skeletal Muscle Laminopathies.
- Author
-
Bhide S, Chandran S, Rajasekaran NS, and Melkani GC
- Subjects
- Humans, Animals, Cardiomyopathies genetics, Cardiomyopathies metabolism, Cardiomyopathies pathology, Cardiomyopathies physiopathology, Myocardium metabolism, Myocardium pathology, Muscular Dystrophies genetics, Muscular Dystrophies metabolism, Muscular Dystrophies pathology, Mutation, Signal Transduction genetics, Lamins genetics, Lamins metabolism, Muscle, Skeletal metabolism, Muscle, Skeletal pathology, Laminopathies genetics, Laminopathies pathology
- Abstract
Nuclear lamins, a type V intermediate filament, are crucial components of the nuclear envelope's inner layer, maintaining nuclear integrity and mediating interactions between the nucleus and cytoplasm. Research on human iPSC-derived cells and animal models has demonstrated the importance of lamins in cardiac and skeletal muscle development and function. Mutations in lamins result in laminopathies, a group of diseases including muscular dystrophies, Hutchison-Gilford progeria syndrome, and cardiomyopathies with conduction defects. These conditions have been linked to disrupted autophagy, mTOR, Nrf2-Keap, and proteostasis signaling pathways, indicating complex interactions between the nucleus and cytoplasm. Despite progress in understanding these pathways, many questions remain about the mechanisms driving lamin-induced pathologies, leading to limited therapeutic options. This review examines the current literature on dysregulated pathways in cardiac and skeletal muscle laminopathies and explores potential therapeutic strategies for these conditions.
- Published
- 2024
- Full Text
- View/download PDF
11. Defining the cardiovascular phenotype of adults with Alström syndrome.
- Author
-
Roy A, Patel L, Yuan M, O'Shea C, Alvior AMB, Charalambides M, Moxon D, Baig S, Bunting KV, Gehmlich K, Geberhiwot T, and Steeds RP
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Young Adult, Adolescent, Electrocardiography, Echocardiography, Cardiomyopathies diagnostic imaging, Cardiomyopathies physiopathology, Phenotype, Alstrom Syndrome complications, Alstrom Syndrome genetics, Alstrom Syndrome physiopathology
- Abstract
Background: >40% of infants with Alström Syndrome (AS) present with a transient, severe cardiomyopathy in the first months of life, with apparent recovery in survivors. One in five individuals then develop a later-onset cardiomyopathy but wide clinical variability is observed, even within the same family. The rationale for this study is to provide a comprehensive evaluation of the cardiovascular phenotype in adults with AS., Methods: Adults attending the National Centre for AS in England were studied. All patients underwent biochemical, 12- lead electrocardiography, echocardiography, and cardiovascular magnetic resonance imaging., Results: 47 adults with AS (64% male; mean age 33 years; 66% white British) were studied. Seven (15%) survived infantile cardiomyopathy and 23 (49%) developed adult-onset cardiomyopathy. Conventional risk factors for cardiovascular disease were present in 39 (83%). Abnormalities were present on biomarkers in 16 (34%), ECG 30 (64%), echocardiography 19 (40%) and CMR 31 (66%). Coronary artery imaging was performed in six (13%), with abnormalities in two. Cardiac, renal, and liver markers were more often impaired in older patients, with impaired left ventricular ejection fraction, reduced global longitudinal strain and late enhancement. 6 (13%) had severe pulmonary hypertension (mean pulmonary artery pressure 46 mmHg) due to left heart disease on invasive testing., Conclusion: Cardiomyopathy is common in adults with AS, complicated in a significant proportion by atherosclerotic coronary artery disease and restrictive cardiomyopathy, confirmed on CMR and invasive testing. With advancing age, cardiovascular complications are compounded by contemporaneous renal and liver disease., Competing Interests: Declaration of competing interest The authors declare that they have no competing interests., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
12. In a Canine Model of Septic Shock, Cardiomyopathy Occurs Independent of Catecholamine Surges and Cardiac Microvascular Ischemia.
- Author
-
Ford VJ, Applefeld WN, Wang J, Sun J, Solomon SB, Klein HG, Feng J, Lertora J, Parizi-Torabi P, Danner RL, Solomon MA, Chen MY, and Natanson C
- Subjects
- Animals, Dogs, Stroke Volume drug effects, Coronary Circulation drug effects, Myocardial Ischemia physiopathology, Myocardial Ischemia blood, Myocardial Ischemia complications, Ventricular Function, Left drug effects, Catecholamines blood, Troponin blood, Staphylococcal Infections microbiology, Staphylococcal Infections complications, Staphylococcal Infections physiopathology, Time Factors, Myocardial Perfusion Imaging methods, Magnetic Resonance Imaging, Disease Models, Animal, Shock, Septic physiopathology, Shock, Septic complications, Shock, Septic blood, Epinephrine blood, Microcirculation drug effects, Cardiomyopathies physiopathology, Cardiomyopathies blood, Cardiomyopathies etiology
- Abstract
Background: High levels of catecholamines are cardiotoxic and associated with stress-induced cardiomyopathies. Using a septic shock model that reproduces the reversible cardiomyopathy seen over 10 days associated with human septic shock, we investigated the effects of catecholamines on microcirculatory perfusion and cardiac dysfunction., Methods and Results: Purpose-bred beagles received intrabronchial Staphylococcus aureus (n=30) or saline (n=6). The septic animals were than randomized to epinephrine (1 μg/kg per minute, n=15) or saline (n=15) infusions from 4 to 44 hours. Serial cardiac magnetic resonance imaging, catecholamine levels, and troponins were collected over 92 hours. Serial adenosine-stress perfusion cardiac magnetic resonance imaging was performed on septic animals randomized to receive saline (n=8 out of 15) or epinephrine (n=8 out of 15). High-dose sedation was given to suppress endogenous catecholamine release. Despite catecholamine levels largely remaining within the normal range throughout, by 48 hours, septic animals receiving saline versus nonseptic animals still developed significant worsening of left ventricular ejection fraction, circumferential strain, and ventricular-aortic coupling. In septic animals that received epinephrine versus saline infusions, plasma epinephrine levels increased 800-fold, but epinephrine produced no significant further worsening of left ventricular ejection fraction, circumferential strain, or ventricular-aortic coupling. Septic animals receiving saline had a significant increase in microcirculatory reserve without troponin elevations. Septic animals receiving epinephrine had decreased edema, blunted microcirculatory perfusion, and elevated troponin levels that persisted for hours after the epinephrine infusion stopped., Conclusions: Cardiac dysfunction during sepsis is not primarily due to elevated endogenous or exogenous catecholamines nor due to decreased microvascular perfusion-induced ischemia. However, epinephrine itself has potentially harmful long-lasting ischemic effects during sepsis including impaired cardiac microvascular perfusion that persists after stopping the infusion.
- Published
- 2024
- Full Text
- View/download PDF
13. Mesenchymal Stem Cells Alleviate Mouse Sepsis-Induced Cardiomyopathy by Inhibiting the NR1D2/LCN2 Pathway.
- Author
-
Jiang C, Wang S, Wang C, Chen G, Xu J, and You C
- Subjects
- Animals, Male, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Cells, Cultured, Oxidative Stress, Ventricular Function, Left, Mice, Apoptosis, Sepsis complications, Sepsis metabolism, Mesenchymal Stem Cell Transplantation, Cardiomyopathies metabolism, Cardiomyopathies pathology, Cardiomyopathies etiology, Cardiomyopathies physiopathology, Cardiomyopathies therapy, Disease Models, Animal, Signal Transduction, Mesenchymal Stem Cells metabolism, Lipocalin-2 metabolism, Lipocalin-2 genetics, Mice, Inbred C57BL
- Abstract
Abstract: Sepsis is characterized as a systemic inflammatory response syndrome resulting from infection, leading to the development of multiple organ dysfunction syndrome. Sepsis-induced cardiomyopathy (SICM) is a frequently encountered condition in clinical settings. Mesenchymal stem cells (MSCs) possess inherent immunomodulatory and anti-inflammatory attributes, rendering them a promising therapeutic approach to reestablish the equilibrium between anti-inflammatory and proinflammatory systems in septic patients. Consequently, MSCs are frequently employed in clinical investigations. In this study, the author established a mouse SICM model through cecal ligation and puncture and administered MSCs through the tail vein. Following successful modeling, the myocardial function and histopathological changes were detected by echocardiography, hematoxylin-eosin staining, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, enzyme-linked immunosorbent assay,, and other experiments. As a result, MSCs demonstrated the ability to enhance myocardial function, promote cardiac tissue repair, suppress inflammatory response, reduce levels of myocardial injury markers, and mitigate oxidative stress. In addition, transcriptome and proteome analyses were conducted. Through differential expression analysis, functional enrichment analysis, and multiomics association analysis, it was revealed that the transcriptional factors nuclear receptor subfamily 1 (NR1D2) and target gene lipocalin 2 (LCN2) played key roles in mediating the effects of MSCs on SICM. JASPAR website and ChIP-qPCR experiment were used to predict and confirm the targeting relationship between them. Subsequent cell coculture experiments and a series of experiments confirmed that MSCs attenuated cardiomyocyte injury by downregulating the expression of NR1D2 and its downstream target gene LCN2. In conclusion, MSCs alleviate mice SICM through inhibiting NR1D2/LCN2 pathway., Competing Interests: The authors declare that there were no conflicts of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
14. Cardiac dysfunction in patients with cirrhosis and acute decompensation.
- Author
-
Gananandan K, Wiese S, Møller S, and Mookerjee RP
- Subjects
- Humans, Liver Transplantation, Portasystemic Shunt, Transjugular Intrahepatic, Liver Cirrhosis complications, Liver Cirrhosis physiopathology, Cardiomyopathies etiology, Cardiomyopathies physiopathology, Cardiomyopathies therapy, Acute-On-Chronic Liver Failure diagnosis, Acute-On-Chronic Liver Failure etiology, Acute-On-Chronic Liver Failure therapy, Acute-On-Chronic Liver Failure physiopathology
- Abstract
The prevalence of cirrhotic cardiomyopathy (CCM) has been reported as high as 60%-70% in patients with liver cirrhosis and is associated with various negative outcomes. There has been a growing understanding of CCM over recent years. Indeed, the development of imaging techniques has enabled new diagnostic criteria to be proposed by the Cirrhotic Cardiomyopathy Consortium. However, important unanswered questions remain over pathophysiological mechanisms, optimal diagnostic modalities and potential treatment options. While there has been an increasing volume of literature evaluating CCM, there is a lack of clarity on its implications in acute decompensation, acute-on-chronic liver failure and following interventions such as transjugular intrahepatic portosystemic shunt insertion and liver transplantation. This review aims to summarise the literature in these challenging domains and suggest where future research should focus. We conclude that systemic inflammation and structural myocardial changes are likely to be crucial in the pathophysiology of the disease, but the relative contribution of different components remains elusive. Furthermore, future studies need to use standardised diagnostic criteria for CCM as well as incorporate newer imaging techniques assessing both myocardial structure and function. Finally, while specific treatments are currently lacking, therapeutics targeting systemic inflammation, microbial dysbiosis and bacterial translocation are promising targets and warrant further research., (© 2024 The Authors. Liver International published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
15. Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment.
- Author
-
Vilches S, Martínez-Avial M, Méndez I, Gómez González C, and Espinosa MÁ
- Subjects
- Humans, Sex Factors, Female, Male, Prealbumin genetics, Prealbumin metabolism, Prevalence, Prognosis, Amyloid Neuropathies, Familial epidemiology, Amyloid Neuropathies, Familial physiopathology, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial genetics, Amyloid Neuropathies, Familial therapy, Cardiomyopathies epidemiology, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis, Cardiomyopathies therapy, Cardiomyopathies genetics
- Abstract
Transthyretin cardiac amyloidosis (ATTR-CA) is characterised by the deposition of transthyretin amyloid fibrils in the heart. ATTR-CA affects both men and women although there is evidence of sex differences in prevalence and clinical presentation. PURPOSE OF REVIEW: This review paper aims to comprehensively examine and synthesise the existing literature on sex differences in ATTR-CA. RECENT FINDINGS: The prevalence of ATTR-CA is higher in males although the male predominance is more apparent in older patients in the wild type form and in TTR genetic variants that predominantly result in a cardiac phenotype in the hereditary variant. Women tend to have less left ventricular hypertrophy (LVH) and a higher ejection fraction at clinical presentation which may contribute to a later diagnosis although the prognosis appears to be similar in both sexes. Female sex is a predictor of a good response to tafamidis 20 mg in TTR polyneuropathy but otherwise there are no data on sex differences in the efficacy of other treatments for ATTR-CA. It is crucial to define specific sex differences in ATTR-CA. A lower cut-off value for LVH in women may be needed to improve diagnosis. It is necessary to increase female representation in clinical trials to better understand possible sex differences in therapeutic management., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
16. The fate and role of the pericytes in myocardial diseases.
- Author
-
Frangogiannis NG
- Subjects
- Humans, Fibrosis, COVID-19, Myocardium pathology, Heart Failure physiopathology, Cardiomyopathies physiopathology, Animals, Myofibroblasts physiology, Pericytes physiology, Myocardial Infarction physiopathology
- Abstract
The adult mammalian heart contains a large population of pericytes that play important roles in homeostasis and disease. In the normal heart, pericytes regulate microvascular permeability and flow. Myocardial diseases are associated with marked alterations in pericyte phenotype and function. This review manuscript discusses the role of pericytes in cardiac homeostasis and disease. Following myocardial infarction (MI), cardiac pericytes participate in all phases of cardiac repair. During the inflammatory phase, pericytes may secrete cytokines and chemokines and may regulate leukocyte trafficking, through formation of intercellular gaps that serve as exit points for inflammatory cells. Moreover, pericyte contraction induces microvascular constriction, contributing to the pathogenesis of 'no-reflow' in ischemia and reperfusion. During the proliferative phase, pericytes are activated by growth factors, such as transforming growth factor (TGF)-β and contribute to fibrosis, predominantly through secretion of fibrogenic mediators. A fraction of pericytes acquires fibroblast identity but contributes only to a small percentage of infarct fibroblasts and myofibroblasts. As the scar matures, pericytes form a coat around infarct neovessels, promoting stabilization of the vasculature. Pericytes may also be involved in the pathogenesis of chronic heart failure, by regulating inflammation, fibrosis, angiogenesis and myocardial perfusion. Pericytes are also important targets of viral infections (such as SARS-CoV2) and may be implicated in the pathogenesis of cardiac complications of COVID19. Considering their role in myocardial inflammation, fibrosis and angiogenesis, pericytes may be promising therapeutic targets in myocardial disease., (© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
17. Loss of ADAM15 in female mice does not worsen pressure overload cardiomyopathy, independent of ovarian hormones.
- Author
-
Krishnan V, Atanasova N, Aujla PK, Hupka D, Owen CA, and Kassiri Z
- Subjects
- Animals, Female, Male, Mice, Inbred C57BL, Calcineurin metabolism, Calcineurin genetics, Disease Models, Animal, Mice, Ventricular Remodeling, NFATC Transcription Factors metabolism, NFATC Transcription Factors genetics, Myocardium metabolism, Myocardium pathology, Fibrosis, Cardiomyopathies physiopathology, Cardiomyopathies metabolism, Cardiomyopathies genetics, Cardiomyopathies etiology, Cardiomyopathies pathology, Sex Factors, Signal Transduction, Ventricular Function, Left, Hypertrophy, Left Ventricular physiopathology, Hypertrophy, Left Ventricular metabolism, Hypertrophy, Left Ventricular genetics, Hypertrophy, Left Ventricular pathology, Hypertrophy, Left Ventricular etiology, Ovariectomy, ADAM Proteins genetics, ADAM Proteins metabolism, ADAM Proteins deficiency, Membrane Proteins genetics, Membrane Proteins metabolism, Mice, Knockout
- Abstract
Cardiac hypertrophy is a common feature in several cardiomyopathies. We previously reported that loss of ADAM15 (disintegrin and metalloproteinase 15) worsened cardiac hypertrophy and dilated cardiomyopathy following cardiac pressure overload. Here, we investigated the impact of ADAM15 loss in female mice following cardiac pressure overload induced by transverse aortic constriction (TAC). Female Adam15
-/- mice developed the same degree of cardiac hypertrophy, dilation, and dysfunction as the parallel female wild-type (WT) mice at 6 wk post-TAC. To determine if this is due to the protective effects of estrogen, which could mask the negative impact of Adam15 loss, WT and Adam15- / - mice underwent ovariectomy (OVx) 2 wk before TAC. Cardiac structure and function analyses were performed at 6 wk post-TAC. OVx similarly impacted females of both genotypes post-TAC. Calcineurin (Cn) activity was increased post-OVx-TAC, and more in Adam15- / - mice; however, this increase was not reflected in the total-to-phospho-NFAT levels. Integrin-α7 expression, which was upstream of Cn activation in male Adam15- / - -TAC mice, remained unchanged in female mice. However, activation of the mitogen-activated protein kinases (ERK, JNK, P38) was greater in Adam15- / - -OVx-TAC than in WT-OVx-TAC mice. In addition, ADAM15 protein levels were significantly increased post-TAC in male but not in female WT mice. Myocardial fibrosis was comparable in non-OVx WT-TAC and Adam15- / - -TAC mice. OVx increased the perivascular fibrosis more in Adam15- / - compared with WT mice post-TAC. Our data demonstrate that loss of ovarian hormones did not fully replicate the male phenotype in the female Adam15- / - mice post-TAC. As ADAM15 levels were increased in males but not in females post-TAC, it is plausible that ADAM15 does not play a prominent role in post-TAC events in female mice. Our findings highlight the significance of factors other than sex hormones in mediating cardiomyopathies in females, which require a more thorough understanding. NEW & NOTEWORTHY Loss of ADAM15 in female mice, unlike the male mice, does not worsen the cardiomyopathy following cardiac pressure overload. Ovariectomy does not worsen the post-TAC cardiomyopathy in female Adam15- / - mice compared with female WT mice. Lack of deleterious impact of Adam15 deficiency in female mice is not because of the protective effects of ovarian hormones but could be due to a less prominent role of ADAM15 in cardiac response to post-TAC remodeling in female mice.- Published
- 2024
- Full Text
- View/download PDF
18. Practical approach for atrial cardiomyopathy characterization in patients with atrial fibrillation.
- Author
-
La Rosa G, Morillo CA, Quintanilla JG, Doltra A, Mont L, Rodríguez-Mañero M, Sarkozy A, Merino JL, Vivas D, Datino T, Calvo D, Pérez-Castellano N, Pérez-Villacastín J, Fauchier L, Lip G, Hatem SN, Jalife J, Sanchis L, Marín F, and Filgueiras-Rama D
- Subjects
- Humans, Atrial Remodeling physiology, Atrial Fibrillation physiopathology, Atrial Fibrillation diagnosis, Atrial Fibrillation complications, Atrial Fibrillation therapy, Atrial Fibrillation etiology, Cardiomyopathies diagnosis, Cardiomyopathies physiopathology, Cardiomyopathies etiology, Cardiomyopathies complications, Heart Atria physiopathology
- Abstract
Atrial fibrillation (AF) causes progressive structural and electrical changes in the atria that can be summarized within the general concept of atrial remodeling. In parallel, other clinical characteristics and comorbidities may also affect atrial tissue properties and make the atria susceptible to AF initiation and its long-term persistence. Overall, pathological atrial changes lead to atrial cardiomyopathy with important implications for rhythm control. Although there is general agreement on the role of the atrial substrate for successful rhythm control in AF, the current classification oversimplifies clinical management. The classification uses temporal criteria and does not establish a well-defined strategy to characterize the individual-specific degree of atrial cardiomyopathy. Better characterization of atrial cardiomyopathy may improve the decision-making process on the most appropriate therapeutic option. We review current scientific evidence and propose a practical characterization of the atrial substrate based on 3 evaluation steps starting with a clinical evaluation (step 1), then assess outpatient complementary data (step 2), and finally include information from advanced diagnostic tools (step 3). The information from each of the steps or a combination thereof can be used to classify AF patients in 4 stages of atrial cardiomyopathy, which we also use to estimate the success on effective rhythm control., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.
- Author
-
Gioia G, Schrutka L, Jozwiak-Nozdrzykowska J, Kresoja KP, Gunold H, Klingel K, Thiele H, Bonderman D, Lurz P, and Rommel KP
- Subjects
- Humans, Female, Male, Aged, Ventricular Function, Left physiology, Retrospective Studies, Echocardiography, Biopsy, Myocardium pathology, Myocardium metabolism, Prealbumin genetics, Prealbumin metabolism, Diagnosis, Differential, Follow-Up Studies, Stroke Volume physiology, Heart Failure physiopathology, Heart Failure diagnosis, Heart Failure complications, Cardiomyopathies diagnosis, Cardiomyopathies physiopathology, Cardiomyopathies etiology, Amyloid Neuropathies, Familial complications, Amyloid Neuropathies, Familial physiopathology, Amyloid Neuropathies, Familial diagnosis
- Abstract
Aims: Transthyretin 'wild-type' amyloid cardiomyopathy (ATTRwt-CM) is a differential diagnosis of heart failure with preserved ejection fraction (HFpEF). The clinical work-up for ATTRwt-CM is challenging. Considering a combination of clinical variables specific for ATTRwt-CM might aid in identifying patients at risk., Methods and Results: Sixty patients (78 ± 6 years, 8% female) were diagnosed with ATTRwt-CM by endomyocardial biopsy. Preserved ejection fraction (LVEF >45%) was present in 41 of the patients. Those were 1:1 propensity score age- and sex-matched to a cohort of patients with HFpEF. ATTRwt-CM patients had less obesity (P = 0.01) and higher septal thickness (IVSd, P < 0.01) as well as more diastolic dysfunction (E/e', P < 0.01). On multivariable regression IVSd > 14 mm, E/e' > 14 and absence of obesity (P > 0.01 for all) were identified as predictors for ATTRwt-CM. A weighted point-based score was derived with IVSd > 14 mm = 1 point; absence of obesity = 2 points; and E/e' > 14 = 3 points. Area under the curve (AUC) for the summation score was 0.91 (0.84-0.97, P < 0.01) and a score of more than 3 points predicted ATTRwt-CM with good sensitivity (78%) and specificity (90%). The score was validated in an external cohort of 142 patients with ATTRwt-CM and 419 HFpEF patients showing sufficient accuracy (AUC 0.91, 0.88-0.94, P < 0.01). A value greater than 3 points demonstrated a high sensitivity (93%) and a negative predictive value of 97%., Conclusions: A score based on basic clinical and echocardiographic features helps to distinguish ATTRwt-CM from typical HFpEF. This could facilitate the diagnostic work-up for these patients and enable earlier disease screening on a large scale., (© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
20. Mitophagy modulation for the treatment of cardiovascular diseases.
- Author
-
Forte M, D'Ambrosio L, Schiattarella GG, Salerno N, Perrone MA, Loffredo FS, Bertero E, Pilichou K, Manno G, Valenti V, Spadafora L, Bernardi M, Simeone B, Sarto G, Frati G, Perrino C, and Sciarretta S
- Subjects
- Humans, Atherosclerosis, Heart Failure physiopathology, Animals, Myocardial Reperfusion Injury, Cardiomyopathies physiopathology, Mitochondria, Heart metabolism, Mitophagy physiology, Cardiovascular Diseases
- Abstract
Background: Defects of mitophagy, the selective form of autophagy for mitochondria, are commonly observed in several cardiovascular diseases and represent the main cause of mitochondrial dysfunction. For this reason, mitophagy has emerged as a novel and potential therapeutic target., Methods: In this review, we discuss current evidence about the biological significance of mitophagy in relevant preclinical models of cardiac and vascular diseases, such as heart failure, ischemia/reperfusion injury, metabolic cardiomyopathy and atherosclerosis., Results: Multiple studies have shown that cardiac and vascular mitophagy is an adaptive mechanism in response to stress, contributing to cardiovascular homeostasis. Mitophagy defects lead to cell death, ultimately impairing cardiac and vascular function, whereas restoration of mitophagy by specific compounds delays disease progression., Conclusions: Despite previous efforts, the molecular mechanisms underlying mitophagy activation in response to stress are not fully characterized. A comprehensive understanding of different forms of mitophagy active in the cardiovascular system is extremely important for the development of new drugs targeting this process. Human studies evaluating mitophagy abnormalities in patients at high cardiovascular risk also represent a future challenge., (© 2024 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.)
- Published
- 2024
- Full Text
- View/download PDF
21. Comparison of prognosis in isolated versus systemic manifestations of cardiac sarcoidosis.
- Author
-
Mactaggart S and Ahmed R
- Subjects
- Humans, Prognosis, Cardiomyopathies diagnosis, Cardiomyopathies etiology, Cardiomyopathies physiopathology, Sarcoidosis diagnosis, Sarcoidosis epidemiology
- Abstract
Background: Isolated cardiac sarcoidosis (iCS) is a poorly understood and under-recognised entity. Previous research has postulated that those with iCS have worsened outcomes compared to those with other manifestations of the disease, however, there have been studies which both support and refute this hypothesis., Purpose of Review: This review will summarise the literature which focuses on differences in the epidemiology, imaging findings and patient outcome of those with isolated cardiac sarcoidosis (iCS) versus 'systemic' cardiac sarcoidosis (sCS) which is not isolated to the heart., Summary: Variations in study design make accurate comparison between current papers challenging, and that the factors which indicate poor prognosis in patients with iCS is not yet fully understood. Current literature suggests those with iCS are more likely to be male, have higher numbers of abnormal uptake patterns on cardiac imaging, and may have poorer prognosis than sCS patients. Multi-centre, prospective studies analysing isolated cardiac sarcoidosis across geographical regions are needed to improve our understanding of this phenomenon and ultimately improve patient outcome., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
22. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.
- Author
-
Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceição I, Weiler M, Berk JL, Gertz M, Gillmore JD, Rush S, Chen J, Zhou W, Kwoh J, Duran JM, Tsimikas S, and Solomon SD
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Oligonucleotides therapeutic use, Treatment Outcome, Cardiomyopathies drug therapy, Cardiomyopathies physiopathology, Prealbumin genetics, Echocardiography, Adult, Stroke Volume physiology, Stroke Volume drug effects, Ventricular Function, Left physiology, Ventricular Function, Left drug effects, Amyloid Neuropathies, Familial drug therapy, Amyloid Neuropathies, Familial physiopathology, Amyloid Neuropathies, Familial complications
- Abstract
Background: Hereditary transthyretin amyloidosis (ATTRv) is associated with polyneuropathy, cardiomyopathy, or both. The effects of eplontersen on cardiac structure and function were assessed., Methods and Results: NEURO-TTRansform was an open-label trial involving 144 adults with ATTRv polyneuropathy (49 patients [34%] with cardiomyopathy) receiving eplontersen throughout and compared with a historical placebo group (n = 60; 30 patients [50%] with cardiomyopathy) from the NEURO-TTR trial at week 65. Treatment effect (eplontersen vs placebo), presented as mean difference (95% confidence interval) was analyzed after adjusting for age, sex, region, baseline value, ATTRv disease stage, previous ATTRv treatment, and V30M transthyretin variant. There were notable differences at baseline between the eplontersen group and historical placebo. In the cardiomyopathy subgroup, 65 weeks of eplontersen treatment was associated with improvement from baseline relative to placebo in left ventricular ejection fraction of 4.3% (95% confidence interval 1.40-21.01; P = .049) and stroke volume 10.64 mL (95% confidence interval 3.99-17.29; P = .002) while the remainder of echocardiographic parameters remained stable., Conclusions: Eplontersen was associated with stable or improved measures of cardiac structure and function vs historical placebo in patients with ATTRv polyneuropathy and cardiomyopathy. Further investigation into eplontersen's effect on transthyretin amyloid cardiomyopathy is being conducted in the CARDIO-TTRansform trial., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
23. Cardiac evaluation of the liver transplant candidate.
- Author
-
Possick S, Khungar V, and Deshpande R
- Subjects
- Humans, Risk Assessment, Patient Selection, Risk Factors, Liver Cirrhosis surgery, Cardiomyopathies etiology, Cardiomyopathies physiopathology, Coronary Angiography, Treatment Outcome, Echocardiography, Liver Transplantation adverse effects, Predictive Value of Tests
- Abstract
Purpose of Review: This review aims to summarize recent changes in the cardiac evaluation of adult liver transplant candidates. Over the last several years, there have been significant advances in the use of coronary computed tomography angiography (CCTA) with and without fractional flow reserve (FFR) and increasingly widespread availability of coronary calcium scoring for risk stratification for obstructive coronary artery disease. This has led to novel strategies for risk stratification in cirrhotic patients being considered for liver transplant and an updated American Heart Association (AHA) position paper on the evaluation of liver and kidney transplant candidates. The diagnosis of cirrhotic cardiomyopathy has been refined. These new diagnostic criteria require that specific echocardiographic parameters are evaluated in all patients. The definition of pulmonary hypertension on echocardiography has been altered and no longer utilizes right atrium (RA) pressure estimates based on inferior vena cava (IVC) size and collapse. This provides more volume neutral estimates of pulmonary pressure., Recent Findings: Although CCTA has outstanding negative predictive value, false positive results are not uncommon and often lead to further testing. Revised diagnostic criteria for cirrhotic cardiomyopathy improve risk stratification for peri-operative volume overload and outcomes. Refined pulmonary hypertension criteria provide improved guidance for right heart catheterization (RHC) and referral to subspecialists. There are emerging data regarding the safety and efficacy of TAVR for severe aortic stenosis in cirrhotic patients., Summary: Increased utilization of noninvasive testing, including CCTA and/or coronary calcium scoring, can improve the negative predictive value of testing for obstructive coronary artery disease and potentially reduce reliance on coronary angiography. Application of the 2020 criteria for cirrhotic cardiomyopathy will improve systolic and diastolic function assessment and subsequent perioperative risk stratification. The use of global strain scores is emphasized, as it provides important information beyond ejection fraction and diastolic parameters. A standardized one-parameter echo cut-off for elevated pulmonary pressures simplifies both evaluation and follow-up. Innovative transcutaneous techniques for valvular stenosis and regurgitation offer new options for patients at prohibitive surgical risk., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Prognostic value of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio in cardiac amyloidosis.
- Author
-
Maccallini M, Barge-Caballero G, Barge-Caballero E, López-Pérez M, Bilbao-Quesada R, González-Babarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, García-Seara J, Bouzas-Mosquera A, and Crespo-Leiro MG
- Subjects
- Humans, Male, Female, Aged, Prognosis, Prospective Studies, Spain epidemiology, Tricuspid Valve diagnostic imaging, Tricuspid Valve physiopathology, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis, Systole, Hypertension, Pulmonary physiopathology, Hypertension, Pulmonary diagnosis, Middle Aged, Registries, Survival Rate trends, Follow-Up Studies, Aged, 80 and over, Pulmonary Wedge Pressure physiology, Amyloidosis physiopathology, Amyloidosis diagnosis, Amyloidosis mortality, Echocardiography methods, Pulmonary Artery physiopathology, Pulmonary Artery diagnostic imaging
- Abstract
Introduction and Objectives: The tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/SPAP) ratio is a noninvasive surrogate of right ventricular to pulmonary circulation that has prognostic implications in patients with heart failure (HF) or pulmonary hypertension. Our purpose was to evaluate the prognostic value of the TAPSE/SPAP ratio in patients with cardiac amyloidosis., Methods: We used the database of the AMIGAL study, a prospective, observational registry of patients with cardiac amyloidosis recruited in 7 hospitals of the Autonomous Community of Galicia, Spain, from January 1, 2018 to October 31, 2022. We selected patients whose baseline TAPSE/SPAP ratio was calculated with transthoracic echocardiography. Long-term survival and survival free of HF hospitalization were assessed by means of 5 different multivariable Cox regression models. Median follow-up was 680 days., Results: We studied 233 patients with cardiac amyloidosis, among whom 209 (89.7%) had transthyretin type. The baseline TAPSE/SPAP ratio correlated significantly with clinical outcomes. Depending on the multivariable model considered, the adjusted hazard ratios estimated per 0.1mm/mmHg increase of baseline TAPSE/SPAP ratio ranged from 0.76 to 0.84 for all-cause mortality. Similarly, the ratios for all-cause mortality of HF hospitalization ranged from 0.79 to 0.84. The addition of the baseline TAPSE/SPAP ratio to the predictive model of the United Kingdom National Amyloidosis Centre resulted in an increase in Harrell's c-statistic from 0.662 to 0.705 for all-cause mortality and from 0.668 to 0.707 for all-cause mortality or HF hospitalization., Conclusions: Reduced TAPSE/SPAP ratio is an independent adverse prognostic marker in patients with cardiac amyloidosis., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Predicting factors for omitting beta-blockers in patients with tachycardia-induced cardiomyopathy after successful catheter ablation for atrial fibrillation.
- Author
-
Takami A, Kato M, Kotake Y, Okamura A, Tomomori T, Kawatani S, and Yamamoto K
- Subjects
- Humans, Male, Female, Retrospective Studies, Aged, Middle Aged, Echocardiography, Treatment Outcome, Tachycardia physiopathology, Tachycardia etiology, Tachycardia drug therapy, Tachycardia diagnosis, Atrial Fibrillation physiopathology, Atrial Fibrillation surgery, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Catheter Ablation methods, Adrenergic beta-Antagonists therapeutic use, Cardiomyopathies diagnosis, Cardiomyopathies etiology, Cardiomyopathies physiopathology, Ventricular Function, Left physiology, Ventricular Function, Left drug effects, Stroke Volume physiology
- Abstract
Tachycardia induces a reduction in the left ventricular ejection fraction (LVEF), which is defined as tachycardia-induced cardiomyopathy (TIC). Conversion to and maintenance of sinus rhythm by catheter ablation can improve LVEF in patients with TIC due to atrial fibrillation (AF). Beta-blockers are mandatory for the treatment of heart failure with reduced LVEF(HFrEF), but the necessity of beta-blockers in TIC patients even after catheter ablation remains unclear. We examined the effect of beta-blockers on cardiac function in TIC patients after catheter ablation. We retrospectively analyzed 124 patients with a history of heart failure and an LVEF of ≤ 50% who underwent catheter ablation for AF. TIC was defined as a ≥ 10% improvement in the baseline LVEF and an improvement to an LVEF of ≥ 50% at 6 months after ablation. Patients with other cardiomyopathy diagnosed before the ablation were excluded. LVEF was significantly increased with the reductions of the left ventricular and left atrial volumes at the 6-month follow-up in all 80 patients with TIC. No beta-blockers were prescribed during the post-ablation follow-up in 21 patients with TIC. The absolute values of and changes in the echocardiographic parameters between before and after ablation were not significantly different between patients with and without beta-blockers after the ablation. A simple score using the history of hospitalization for heart failure and use of beta-blockers or diuretics prior to ablation was useful in identifying TIC patients who did not need prescription of beta-blockers after catheter ablation. LVEF similarly improved in both patients with and without prescription of beta-blockers after the ablation. Beta-blockers may not need to be prescribed after successful catheter ablation for AF in LVEF of ≤ 50% patients without other cause of cardiomyopathy diagnosed before the ablation, a history of hospitalization for heart failure and prescription of beta-blockers and diuretics before the ablation., (© 2024. Springer Nature Japan KK, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
26. Retrograde Conduction in Left Bundle Branch Block: Insights From Left Bundle Branch Pacing.
- Author
-
Ponnusamy SS, Basil W, Ganesan V, Syed T, Ramalingam V, Mariappan S, Anand V, Murugan S, Kumar M, and Vijayaraman P
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Heart Failure therapy, Heart Failure physiopathology, Heart Failure complications, Electrocardiography, Cardiac Resynchronization Therapy methods, Cardiomyopathies physiopathology, Cardiomyopathies therapy, Cardiomyopathies complications, Cardiac Pacing, Artificial methods, Stroke Volume physiology, Bundle-Branch Block physiopathology, Bundle-Branch Block therapy, Bundle of His physiopathology
- Abstract
Background: Biventricular pacing is a well-established therapy for patients with heart failure (HF), left bundle branch block (LBBB) and left ventricular (LV) dysfunction. Left bundle branch pacing (LBBP) has emerged as an alternative to biventricular pacing., Objectives: The aim of this study was to assess the retrograde conduction properties of the left bundle branch in patients with nonischemic cardiomyopathy and LBBB during LBBP and its clinical implications., Methods: Patients undergoing successful LBBP for nonischemic cardiomyopathy with LV ejection fraction (LVEF) ≤35% and LBBB were included. Continuous recording of His potential was performed using a quadripolar catheter. Unidirectional block was defined as retrograde His bundle activation during LBBP with stimulus to His potential (SH) duration less than or equal to antegrade HV interval and bidirectional block as VH dissociation or SH duration greater than HV interval. HF hospitalization, ventricular arrhythmias, and mortality were documented., Results: A total of 165 patients were included. The mean follow-up duration was 21.8 ± 13.1 months. Bidirectional block (group I) was observed in 82% (n = 136), and these patients were noted to have advanced HF stage and prolonged baseline QRS duration. Unidirectional block (group II) with intact retrograde conduction was observed in 18% (n = 29) and was associated with narrow paced QRS duration and higher LVEF during follow-up. Super-response (LVEF ≥50%) was observed in 54.4% (n = 74) in group I compared with 73.3% (n = 22) in group II (P = 0.03). The OR for LVEF normalization was 4.1 (95% CI: 1.26-13.97; P = 0.02), with unidirectional block compared with bidirectional block in patients with LBBB and LV dysfunction. Adverse clinical outcomes as measured by a composite of HF hospitalization, ventricular arrhythmias, and mortality were significantly higher in group I compared with group II (12.5% vs 0%; P = 0.04)., Conclusions: Bidirectional block in LBBB was characterized by advanced HF symptoms, while unidirectional block was associated with better clinical outcomes after cardiac resynchronization therapy by LBBP., Competing Interests: Funding Support and Author Disclosures Dr Ponnusamy is a consultant for Medtronic. Dr Vijayaraman is a speaker and consultant for and has received research and fellowship support from Medtronic; is a consultant for Abbott, Biotronik, and Boston Scientific; and holds a patent on an HBP delivery tool. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Left bundle branch block-induced cardiomyopathy: A distinctive form of cardiomyopathy that might require a dedicated form of treatment.
- Author
-
Kloosterman M, Loh KP, and van Veen TAB
- Subjects
- Humans, Bundle-Branch Block physiopathology, Bundle-Branch Block therapy, Bundle-Branch Block etiology, Cardiomyopathies therapy, Cardiomyopathies physiopathology, Cardiomyopathies etiology, Cardiomyopathies diagnosis, Electrocardiography
- Abstract
Competing Interests: Disclosures The authors have no conflicts of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
28. [Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report].
- Author
-
Golubovskaya DP, Dren' EV, Yurkina AV, Pecherina TB, and Barbarash OL
- Subjects
- Humans, Male, Fatal Outcome, Echocardiography methods, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial complications, Amyloid Neuropathies, Familial physiopathology, Middle Aged, Cardiomyopathies diagnosis, Cardiomyopathies etiology, Cardiomyopathies physiopathology, Heart Failure etiology, Heart Failure diagnosis, Disease Progression
- Abstract
Despite the presence of various signs of cardiac amyloidosis ("red flags"), the introduction into routine practice of new non-invasive diagnostic methods (Speckle Tracking technology using echocardiography, myocardial scintigraphy with technetium pyrophosphate, genetic testing, screening for free light chains of immunoglobulins to exclude AL-amyloidosis), which have high specificity and sensitivity, transthyretinic (ATTR) cardiomyopathy is still a difficult to diagnose disease, especially in the early stages when treatment is most effective. The article presents a clinical case of ATTR-amyloidosis with predominant heart damage, manifested by severe diastolic heart failure resistant to treatment. The timing, from the moment of the first episode of decompensation of heart failure to death, is 4 months, which confirms the rapid progression of severe biventricular dysfunction of the heart. Despite the presence of cardiac and extracardial "red flags" of ATTR-amyloidosis in the patient, the diagnosis was established at autopsy. The paper analyzes possible errors of early diagnosis at the outpatient and inpatient stages of patient management.
- Published
- 2024
- Full Text
- View/download PDF
29. Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy.
- Author
-
Ezad SM, McEntegart M, Dodd M, Didagelos M, Sidik N, Li Kam Wa M, Morgan HP, Pavlidis A, Weerackody R, Walsh SJ, Spratt JC, Strange J, Ludman P, Chiribiri A, Clayton T, Petrie MC, O'Kane P, and Perera D
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Percutaneous Coronary Intervention methods, Treatment Outcome, Coronary Angiography, Cardiomyopathies surgery, Cardiomyopathies physiopathology, Ventricular Dysfunction, Left physiopathology, Myocardial Ischemia surgery, Myocardial Ischemia physiopathology, Myocardial Revascularization methods
- Abstract
Background: Complete revascularization of coronary artery disease has been linked to improved outcomes in patients with preserved left ventricular (LV) function., Objectives: This study sought to identify the impact of complete revascularization in patients with severe LV dysfunction., Methods: Patients enrolled in the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial were eligible if baseline/procedural angiograms and viability studies were available for analysis by independent core laboratories. Anatomical and viability-guided completeness of revascularization were measured by the coronary and myocardial revascularization indices (RI
coro and RImyo ), respectively, where RIcoro = (change in British Cardiovascular Intervention Society Jeopardy score [BCIS-JS]) / (baseline BCIS-JS) and RImyo = (number of revascularized viable segments) / (number of viable segments supplied by diseased vessels). The percutaneous coronary intervention (PCI) group was classified as having complete or incomplete revascularization by median RIcoro and RImyo . The primary outcome was death or hospitalization for heart failure., Results: Of 700 randomized patients, 670 were included. The baseline BCIS-JS and SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores were 8 (Q1-Q3: 6-10) and 22 (Q1-Q3: 15-29), respectively. In those patients assigned to PCI, median RIcoro and RImyo values were 67% and 85%, respectively. Compared with the group assigned to optimal medical therapy alone, there was no difference in the likelihood of the primary outcome in those patients receiving complete anatomical or viability-guided revascularization (HR: 0.90; 95% CI: 0.62-1.32; and HR: 0.95; 95% CI: 0.66-1.35, respectively). A sensitivity analysis by residual SYNTAX score showed no association with outcome., Conclusions: In patients with severe LV dysfunction, neither complete anatomical nor viability-guided revascularization was associated with improved event-free survival compared with incomplete revascularization or treatment with medical therapy alone. (Revascularization for Ischemic Ventricular Dysfunction) [REVIVED-BCIS2]; NCT01920048)., Competing Interests: Funding Support and Author Disclosures The trial was funded by the National Institute for Health and Care Research (UK) Health Technology Assessment Program (NIHR 10/57/67); and the present work was supported by the British Heart Foundation (FS/CRTF/21/24118, RE/18/2/34213 and RE/18/6/34217). The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
30. Prevalence and clinical significance of low QRS voltages in healthy individuals, athletes, and patients with cardiomyopathy: implications for sports pre-participation cardiovascular screening.
- Author
-
Pelliccia A, Drezner JA, Zorzi A, and Corrado D
- Subjects
- Humans, Prevalence, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac prevention & control, Predictive Value of Tests, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac physiopathology, Arrhythmias, Cardiac epidemiology, Heart Rate physiology, Action Potentials, Prognosis, Risk Assessment, Risk Factors, Mass Screening methods, Sports physiology, Clinical Relevance, Electrocardiography, Athletes, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis, Cardiomyopathies epidemiology
- Abstract
Low QRS voltages (LQRSV), defined as a QRS amplitude from peak to nadir < 0.5 mV in all limb leads, are an emerging diagnostic finding on the electrocardiogram (ECG). In healthy individuals and athletes, LQRSV are rare (2.2-4% of elite athletes, 0.5% of recreational athletes, and 0.3% of sedentary individuals). LQRSV athletes commonly show ventricular arrhythmias (VAs) on exercise, and up to 40% of those with LQRSV and VAs have late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR). The prevalence of LQRSV in arrhythmogenic cardiomyopathy ranges from 17-40%, predicts left ventricular (LV) involvement, and is correlated with more extensive LGE replacement on CMR. In hypertrophic cardiomyopathy (HCM), LQRSV ranges from 0.7-11%. LQRSV-HCM patients have more segments with LGE, despite relatively smaller LV mass, suggesting a more advanced clinical stage and a worse prognosis. In dilated cardiomyopathy (DCM), LQRSV range from 6-7%, but may be higher (36%) in certain genetic forms of DCM. On a follow-up, LQRSV are independently associated with incident cardiac events, such as sudden death, sustained ventricular arrhythmia, or appropriate internal cardioverter defibrillator discharge. In cardiac amyloid, LQRSV range from 34-66% and demonstrate a negative prognostic value, with worse clinical outcomes regardless of underlying biologic, genetic, and clinical variables. In conclusion, LQRSV deserve careful consideration for exclusion of arrhythmogenic substrates in healthy individuals, athletes, and patients. While additional research is needed, it is reasonable that LQRSV should trigger clinical investigation to exclude underlying diseases at risk of life-threatening arrhythmias., Competing Interests: Conflict of interest: none declared., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
31. The value of myocardial contraction fraction and long-axis strain to predict late gadolinium enhancement in multiple myeloma patients with secondary cardiac amyloidosis.
- Author
-
Hu M, Song Y, Yang C, Wang J, Zhu W, Kan A, Yang P, Dai J, Yu H, and Gong L
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Retrospective Studies, Stroke Volume, Ventricular Function, Left, Contrast Media, Magnetic Resonance Imaging methods, Cardiomyopathies diagnostic imaging, Cardiomyopathies physiopathology, Cardiomyopathies etiology, ROC Curve, Magnetic Resonance Imaging, Cine methods, Multiple Myeloma diagnostic imaging, Multiple Myeloma complications, Multiple Myeloma pathology, Amyloidosis diagnostic imaging, Amyloidosis physiopathology, Amyloidosis pathology, Gadolinium, Myocardial Contraction
- Abstract
The aim of this study is to assess the effectiveness of conventional and two additional functional markers derived from standard cardiac magnetic resonance (CMR) images in detecting the occurrence of late gadolinium enhancement (LGE) in patients with secondary cardiac amyloidosis (CA) related to multiple myeloma (MM). This study retrospectively included 32 patients with preserved ejection fraction (EF) who had MM-CA diagnosed consecutively. Conventional left ventricular (LV) function markers and two additional functional markers, namely myocardial contraction fraction (MCF) and LV long-axis strain (LAS), were obtained using commercial cardiac post-processing software. Logistic regression analyses and receiver operating characteristic (ROC) analysis were performed to evaluate the predictive performances. (1) There were no notable distinctions in clinical features between the LGE+ and LGE- groups, with the exception of a reduced systolic blood pressure in the former (105.60 ± 18.85 mmHg vs. 124.50 ± 20.95 mmHg, P = 0.022). (2) Patients with MM-CA presented with intractable heart failure with preserved ejection fraction (HFpEF). The LVEF in the LGE+ group exhibited a greater reduction (54.27%, IQR 51.59-58.39%) in comparison to the LGE- group (P < 0.05). And MM-CA patients with LGE+ had significantly higher LVMI (90.15 ± 23.69 g/m
2 ), lower MCF (47.39%, IQR 34.28-54.90%), and the LV LAS were more severely damaged (- 9.94 ± 3.42%) than patients with LGE- (all P values < 0.05). (3) The study found that MCF exhibited a significant independent association with LGE, as indicated by an odds ratio of 0.89 (P < 0.05). The cut-off value for MCF was determined to be 64.25% with a 95% confidence interval ranging from 0.758 to 0.983. The sensitivity and specificity of this association were calculated to be 95% and 83%, respectively. MCF is a simple reproducible predict marker of LGE in MM-CA patients. It is a potentially CMR-based method that promise to reduce scan times and costs, and boost the accessibility of CMR., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
32. Paradoxical progress of function and fibrosis in FLNC cardiomyopathy after therapy.
- Author
-
Li Y, Xu Y, and Chen Y
- Subjects
- Humans, Male, Female, Cardiomyopathies etiology, Cardiomyopathies physiopathology, Cardiomyopathies therapy, Fibrosis
- Published
- 2024
- Full Text
- View/download PDF
33. Zolpidem-triggered atrial fibrillation in a patient with cardiomyopathy: a case report.
- Author
-
Li X and Jin Y
- Subjects
- Humans, Male, Adult, Suicide, Attempted, Drug Overdose diagnosis, Heart Rate drug effects, Pyridines adverse effects, Zolpidem adverse effects, Atrial Fibrillation drug therapy, Atrial Fibrillation diagnosis, Atrial Fibrillation chemically induced, Cardiomyopathies chemically induced, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis
- Abstract
Background: Zolpidem is a non-benzodiazepine hypnotic widely used to manage insomnia. Zolpidem-triggered atrial fibrillation (AF) in patients with cardiomyopathy has never been reported before., Case Presentation: A 40-year-old man with Duchenne muscular dystrophy-related cardiomyopathy attempted suicide and developed new-onset AF after zolpidem overdose. One year before admission, the patient visited our clinic due to chest discomfort and fatigue after daily walks for 1 month; both electrocardiography (ECG) and 24-hour Holter ECG results did not detect AF. After administration of cardiac medication (digoxin 0.125 mg/day, spironolactone 40 mg/day, furosemide 20 mg/day, bisoprolol 5 mg/day, sacubitril/valsartan 12/13 mg/day), he felt better. AF had never been observed before this admission via continuous monitoring during follow-up. Sixteen days before admission, the patient saw a sleep specialist and started zolpidem tartrate tablets (10 mg/day) due to insomnia for 6 months; ECG results revealed no significant change. The night before admission, the patient attempted suicide by overdosing on 40 mg of zolpidem after an argument, which resulted in severe lethargy. Upon admission, his ECG revealed new-onset AF, necessitating immediate cessation of zolpidem. Nine hours into admission, AF spontaneously terminated into normal sinus rhythm. Results from the ECG on the following days and the 24-hour Holter ECG at 1-month follow-up showed that AF was not detected., Conclusions: This study provides valuable clinical evidence indicating that zolpidem overdose may induce AF in patients with cardiomyopathy. It serves as a critical warning for clinicians when prescribing zolpidem, particularly for patients with existing heart conditions. Further large-scale studies are needed to validate this finding and to explore the mechanisms between zolpidem and AF., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
34. Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy.
- Author
-
Ladefoged B, Pedersen AD, Seefeldt J, Nielsen BRR, Eiskjær H, Lichscheidt E, Clemmensen T, Gillmore JD, and Poulsen SH
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Peptide Fragments metabolism, Exercise Test, Denmark, Cardiac Catheterization, Ventricular Function, Left physiology, Biopsy, Myocardial Contraction physiology, Biomarkers blood, Biomarkers metabolism, Ventricular Function, Right physiology, Ventricular Pressure, Prealbumin metabolism, Prealbumin genetics, Cardiomyopathies physiopathology, Cardiomyopathies metabolism, Amyloid Neuropathies, Familial physiopathology, Amyloid Neuropathies, Familial metabolism, Amyloid Neuropathies, Familial genetics, Hemodynamics physiology, Mitochondria, Heart metabolism, Oxidative Phosphorylation, Natriuretic Peptide, Brain metabolism
- Abstract
Background: Wild-type transthyretin amyloid (ATTRwt) cardiomyopathy is increasingly recognized in the development of heart failure. The link between cardiac performance, hemodynamics, and mitochondrial function in disease stages of ATTRwt has not previously been studied but may provide new insights into the pathophysiology and clinical performance of the patients., Methods and Results: The study investigated 47 patients diagnosed with ATTRwt at Aarhus University Hospital, Denmark. Patients were stratified according to the disease stages of the National Amyloidosis Centre (NAC) as NAC I with low levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) (NAC I-L, n=14), NAC I with high levels NT-proBNP (NAC I-H, n=20), and NAC II-III (n=13). Exercise testing with simultaneous right heart catheterization was performed in all patients. Endomyocardial biopsies were collected from the patients and the mitochondrial oxidative phosphorylation capacity was assessed. All NAC disease groups, even in the NAC I-L group, a significant abnormal increase in biventricular filling pressures were noted during exercise while the filling pressures was normal or near normal at rest. The inotropic response to exercise was reduced with diminished increase in cardiac output which was significantly more pronounced in the NAC I-H (Diff. -2.4, 95% CI (-4.2: -0.7), P =0.00) and the NAC II-III group (Diff: -3.1 L/min, 95% CI (-5.2: -1.1), P =0.00) compared with the NAC I-L group. The pulmonary artery wedge pressure to cardiac output ratio at peak exercise was significantly different between NAC I-L and NAC II-III (Diff: 1.6 mm Hg*min/L, 95% CI (0.01:3.3, P =0.04)). Patients with ATTRwt had a reduced oxidative phosphorylation capacity which correlated to left ventricular mass but not to cardiac output capacity., Conclusions: An abnormal restrictive left ventricle and right ventricle response to exercise was demonstrated, even present in patients with early-stage ATTRwt. In more advanced disease stages a progressive impairment of the pressure-flow relationship was noted. The myocyte energetics is deranged but not associated to the contractile reserve or restrictive filling characteristics in ATTRwt.
- Published
- 2024
- Full Text
- View/download PDF
35. Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis.
- Author
-
Ioannou A, Fumagalli C, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri L, Moody W, Steeds RP, Petrie A, Whelan C, Wechalekar A, Lachmann H, Hawkins PN, Solomon SD, Gillmore JD, and Fontana M
- Subjects
- Humans, Male, Female, Retrospective Studies, Prognosis, Aged, Middle Aged, Follow-Up Studies, Walk Test methods, Amyloid Neuropathies, Familial mortality, Amyloid Neuropathies, Familial physiopathology, Amyloid Neuropathies, Familial diagnosis, Cardiomyopathies physiopathology, Cardiomyopathies mortality, Cardiomyopathies diagnosis
- Abstract
Background: The 6-minute walk test (6MWT) represents a comprehensive functional assessment that is commonly used in patients with heart failure; however, data are lacking in patients with transthyretin cardiac amyloidosis (ATTR-CA)., Objectives: This study aimed to assess the prognostic importance of the 6MWT in patients with ATTR-CA., Methods: A retrospective analysis of patients diagnosed with ATTR-CA at the National Amyloidosis Centre who underwent a baseline 6MWT between 2011 and 2023 identified 2,141 patients, of whom 1,118 had follow-up at 1 year., Results: The median baseline 6MWT distance was 347 m (Q1-Q3: 250-428 m) and analysis by quartiles demonstrated an increased death rate with each distance reduction (deaths per 100 person-years: 6.3 vs 9.2 vs 13.6 vs 19.0; log-rank P < 0.001). A 6MWT distance of <350 m was associated with a 2.2-fold higher risk of mortality (HR: 2.15; 95% CI: 1.85-2.50; P < 0.001), with a similar increased risk across National Amyloidosis Centre disease stages (P for interaction = 0.761) and genotypes (P for interaction = 0.172). An absolute (reduction of >35 m) and relative worsening (reduction of >5%) of 6MWT at 1 year was associated with an increased risk of mortality (HR: 1.80; 95% CI: 1.51-2.15; P < 0.001 and HR: 1.89; 95% CI: 1.59-2.24; P < 0.001, respectively), which was similar across the aforementioned subgroups. When combined with established measures of disease progression (N-terminal pro-B-type natriuretic peptide progression and outpatient diuretic intensification), each incremental increase in progression markers was associated with an increased death rate (deaths per 100 person-years: 7.6 vs 13.9 vs 22.4 vs 32.9; log-rank P < 0.001)., Conclusions: The baseline 6MWT distance can refine risk stratification beyond traditional prognosticators. A worsening 6MWT distance can stratify disease progression and, when combined with established markers, identifies patients at the highest risk of mortality., Competing Interests: Funding Support and Author Disclosures Dr Wechalekar has received consulting income from Alexia, AstraZeneca, Janssen, Attralus, and Prothena. Dr Solomon has received research grants from Alexion, Alnylam, AstraZeneca, Bellerophon, Bayer, BMS, Cytokinetics, Eidos, Gossamer, GSK, Ionis, Lilly, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. Dr Gilmore has received consulting income from Ionis, Eidos, Intellia, Alnylam, and Pfizer. Dr Fontana is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/21/33447); and has received consulting income from Intellia, Novo Nordisk, Pfizer, Eidos, Prothena, Akcea, Alnylam, Caleum, Alexion, Janssen, Ionis, and AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Temporal Trends in Clinical Characteristics and Outcomes for Peripartum Cardiomyopathy: The Nationwide Multicenter Registry Over 20 Years.
- Author
-
Bak M, Youn JC, Bae DH, Lee JH, Lee S, Cho DH, and Choi JO
- Subjects
- Humans, Female, Adult, Pregnancy, Republic of Korea epidemiology, Risk Factors, Time Factors, Heart Transplantation trends, Heart Transplantation statistics & numerical data, Prognosis, Ventricular Function, Left, Stroke Volume, Cause of Death trends, Hospitalization trends, Hospitalization statistics & numerical data, Puerperal Disorders epidemiology, Puerperal Disorders therapy, Puerperal Disorders mortality, Puerperal Disorders physiopathology, Retrospective Studies, Heart Failure epidemiology, Heart Failure mortality, Heart Failure therapy, Heart Failure physiopathology, Incidence, Registries, Cardiomyopathies epidemiology, Cardiomyopathies therapy, Cardiomyopathies physiopathology, Cardiomyopathies mortality, Peripartum Period, Pregnancy Complications, Cardiovascular epidemiology, Pregnancy Complications, Cardiovascular therapy
- Abstract
Background: Although peripartum cardiomyopathy (PPCM) is a fatal disease affecting young patients and fetuses, little is known about its recent prognosis and risk factors. This study investigated temporal trends in clinical characteristics and outcomes for PPCM in a nationwide multicenter registry., Methods and Results: The study population comprised 340 patients (mean age, 33 years) who were diagnosed with PPCM between January 2000 and September 2022 in 26 tertiary hospitals in South Korea. PPCM was defined as heart failure with left ventricular ejection fraction ≤45% and no previously known cardiac disease. The main study outcomes included time to the first occurrence of all-cause death, heart transplantation, and cardiovascular hospitalization. The diagnosis of PPCM cases increased notably during the study period ( P <0.001). However, clinical outcomes showed no significant improvement (all-cause death for 10 years: 0.9% [2000-2010] versus 2.3% [2011-2022], P =0.450; all-cause death and heart transplantation for 10 years: 3.6% [2000-2010] versus 3.0% [2011-2022] P =0.520; all-cause death, heart transplantation, and cardiovascular hospitalization for 10 years: 11.7% [2000-2010] versus 19.8% [2011-2022], P =0.240). High body mass index (hazard ratio [HR], 1.106 [95% CI, 1.024-1.196]; P =0.011), the presence of gestational diabetes (HR, 5.346 [95% CI, 1.778-16.07]; P =0.002), and increased baseline left ventricular end-diastolic dimension (HR, 1.078 [95% CI, 1.002-1.159]; P =0.044) were significant risk factors for poor prognosis., Conclusions: While the incidence of PPCM has increased over the past 20 years, the prognosis has not improved significantly. Timely management and close follow-up are necessary for high-risk patients with PPCM with high body mass index, gestational diabetes, or large left ventricular end-diastolic dimension.
- Published
- 2024
- Full Text
- View/download PDF
37. Turning Meters Into Years: Walking to Survive Transthyretin Cardiac Amyloidosis.
- Author
-
Masri A
- Subjects
- Humans, Walking physiology, Male, Aged, Amyloid Neuropathies, Familial physiopathology, Cardiomyopathies physiopathology
- Abstract
Competing Interests: Funding Support and Author Disclosures Dr Masri has received research grants from Pfizer, Ionis, Attralus, and Cytokinetics; and has received personal fees from Cytokinetics, Bristol Myers Squibb, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Prothena, BioMarin, AstraZeneca, and Tenaya.
- Published
- 2024
- Full Text
- View/download PDF
38. Heart Failure, Atrial Fibrillation, and Predictors of Arrhythmia-Induced Cardiomyopathy.
- Author
-
Bergonti M and Conte G
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Risk Factors, Atrial Fibrillation complications, Atrial Fibrillation physiopathology, Cardiomyopathies physiopathology, Cardiomyopathies etiology, Cardiomyopathies complications, Heart Failure etiology, Heart Failure physiopathology
- Published
- 2024
- Full Text
- View/download PDF
39. Reply: Heart Failure, Atrial Fibrillation, and Predictors of Arrhythmia-Induced Cardiomyopathy.
- Author
-
Schach C, Körtl T, Lavall D, Wachter R, Sohns C, and Sossalla S
- Subjects
- Humans, Atrial Fibrillation complications, Cardiomyopathies physiopathology, Cardiomyopathies etiology, Cardiomyopathies complications, Heart Failure etiology, Heart Failure physiopathology
- Published
- 2024
- Full Text
- View/download PDF
40. Left Atrial Myopathy in Heart Failure With Preserved Ejection: Don't Raise the Roof!
- Author
-
Patel RB and Shah SJ
- Subjects
- Humans, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis, Cardiomyopathies complications, Cardiomyopathies diagnostic imaging, Male, Atrial Function, Left physiology, Aged, Ventricular Function, Left physiology, Female, Heart Failure physiopathology, Heart Failure diagnosis, Stroke Volume physiology, Heart Atria physiopathology, Heart Atria diagnostic imaging
- Abstract
Competing Interests: Dr Shah received research grants from AstraZeneca, Corvia, and Pfizer and consulting fees from Abbott, Alleviant, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Imara, Impulse Dynamics, Intellia, Ionis, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sardocor, Shifamed, Tenax, Tenaya, and Ultromics. Dr Patel reports no conflicts.
- Published
- 2024
- Full Text
- View/download PDF
41. Assessment of Myocardial Viability in Ischemic Cardiomyopathy With Reduced Left Ventricular Function Undergoing Coronary Artery Bypass Grafting.
- Author
-
Arjomandi Rad A, Tserioti E, Magouliotis DE, Vardanyan R, Samiotis IV, Skoularigis J, Ariff B, Xanthopoulos A, Triposkiadis F, Casula R, and Athanasiou T
- Subjects
- Humans, Cardiomyopathies physiopathology, Cardiomyopathies surgery, Cardiomyopathies diagnosis, Cardiomyopathies etiology, Coronary Artery Disease surgery, Coronary Artery Disease physiopathology, Coronary Artery Disease diagnosis, Coronary Artery Disease complications, Echocardiography, Stress methods, Myocardium pathology, Tissue Survival, Tomography, Emission-Computed, Single-Photon, Ventricular Dysfunction, Left physiopathology, Ventricular Dysfunction, Left etiology, Coronary Artery Bypass adverse effects, Myocardial Ischemia physiopathology, Myocardial Ischemia surgery, Myocardial Ischemia diagnosis, Myocardial Ischemia complications, Ventricular Function, Left physiology
- Abstract
Background: We aim to provide a comprehensive review of the current state of knowledge of myocardial viability assessment in patients undergoing coronary artery bypass grafting (CABG), with a focus on the clinical markers of viability for each imaging modality. We also compare mortality between patients with viable myocardium and those without viability who undergo CABG., Methods: A systematic database search with meta-analysis was conducted of comparative original articles (both observations and randomized controlled studies) of patients undergoing CABG with either viable or nonviable myocardium, in EMBASE, MEDLINE, Cochrane database, and Google Scholar, from inception to 2022. Imaging modalities included were dobutamine stress echocardiography (DSE), cardiac magnetic resonance (CMR), single-photon emission computed tomography (SPECT), and positron emission tomography (PET)., Results: A total of 17 studies incorporating a total of 2317 patients were included. Across all imaging modalities, the relative risk of death post-CABG was reduced in patients with versus without viability (random-effects model: odds ratio: 0.42; 95% confidence interval: 0.29-0.61; p < 0.001). Imaging for myocardial viability has significant clinical implications as it can affect the accuracy of the diagnosis, guide treatment decisions, and predict patient outcomes. Generally, based on local availability and expertise, either SPECT or DSE should be considered as the first step in evaluating viability, while PET or CMR would provide further evaluation of transmurality, perfusion metabolism, and extent of scar tissue., Conclusion: The assessment of myocardial viability is an essential component of preoperative evaluation in patients with ischemic heart disease undergoing surgical revascularization. Careful patient selection and individualized assessment of viability remain paramount., (© 2024 The Author(s). Clinical Cardiology published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
42. Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review.
- Author
-
Nativi-Nicolau J, Yilmaz A, Dasgupta N, Macey R, Cochrane J, Peatman J, Summers C, Luth J, and Zolty R
- Subjects
- Humans, Hospitalization statistics & numerical data, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial physiopathology, Clinical Trials as Topic methods, Heart Failure physiopathology, Heart Failure diagnosis, Walk Test methods, Cardiomyopathies physiopathology, Cardiomyopathies diagnosis
- Abstract
Aim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. Objective: To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. Method: A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. Results: Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. Conclusion: The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.
- Published
- 2024
- Full Text
- View/download PDF
43. ECG-only explainable deep learning algorithm predicts the risk for malignant ventricular arrhythmia in phospholamban cardiomyopathy.
- Author
-
van de Leur RR, de Brouwer R, Bleijendaal H, Verstraelen TE, Mahmoud B, Perez-Matos A, Dickhoff C, Schoonderwoerd BA, Germans T, Houweling A, van der Zwaag PA, Cox MGPJ, Peter van Tintelen J, Te Riele ASJM, van den Berg MP, Wilde AAM, Doevendans PA, de Boer RA, and van Es R
- Subjects
- Humans, Male, Female, Risk Assessment methods, Middle Aged, Cardiomyopathies diagnosis, Cardiomyopathies physiopathology, Cardiomyopathies etiology, Adult, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular physiopathology, Tachycardia, Ventricular etiology, Retrospective Studies, Deep Learning, Electrocardiography methods, Calcium-Binding Proteins metabolism, Algorithms
- Abstract
Background: Phospholamban (PLN) p.(Arg14del) variant carriers are at risk for development of malignant ventricular arrhythmia (MVA). Accurate risk stratification allows timely implantation of intracardiac defibrillators and is currently performed with a multimodality prediction model., Objective: This study aimed to investigate whether an explainable deep learning-based approach allows risk prediction with only electrocardiogram (ECG) data., Methods: A total of 679 PLN p.(Arg14del) carriers without MVA at baseline were identified. A deep learning-based variational auto-encoder, trained on 1.1 million ECGs, was used to convert the 12-lead baseline ECG into its FactorECG, a compressed version of the ECG that summarizes it into 32 explainable factors. Prediction models were developed by Cox regression., Results: The deep learning-based ECG-only approach was able to predict MVA with a C statistic of 0.79 (95% CI, 0.76-0.83), comparable to the current prediction model (C statistic, 0.83 [95% CI, 0.79-0.88]; P = .054) and outperforming a model based on conventional ECG parameters (low-voltage ECG and negative T waves; C statistic, 0.65 [95% CI, 0.58-0.73]; P < .001). Clinical simulations showed that a 2-step approach, with ECG-only screening followed by a full workup, resulted in 60% less additional diagnostics while outperforming the multimodal prediction model in all patients. A visualization tool was created to provide interactive visualizations (https://pln.ecgx.ai)., Conclusion: Our deep learning-based algorithm based on ECG data only accurately predicts the occurrence of MVA in PLN p.(Arg14del) carriers, enabling more efficient stratification of patients who need additional diagnostic testing and follow-up., Competing Interests: Disclosures The UMC Groningen, which employs several of the authors, received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc, Novo Nordisk, and Roche (outside the submitted work). Rudolf A. de Boer has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche (outside the submitted work). Rutger R. van de Leur and René van Es are cofounders, shareholders, and board members of Cordys Analytics B.V., a spin-off of the UMC Utrecht that has licensed AI-ECG algorithms, not including the algorithm studied in the current manuscript. The UMC Utrecht receives royalties from Cordys Analytics for potential future revenues. Pieter A. Doevendans is founder and shareholder of HeartEye B.V., an ECG-device company. The other authors declare that there is no conflict of interest., (Copyright © 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Inflammation and Myocardial Blood Flow in Cardiac Sarcoidosis.
- Author
-
Parihar AS, Valenta I, Mikhail S, Imperiale A, and Schindler TH
- Subjects
- Humans, Fluorodeoxyglucose F18, Prognosis, Inflammation physiopathology, Myocardium pathology, Radiopharmaceuticals, Positron-Emission Tomography, Microcirculation, Myocarditis physiopathology, Myocarditis diagnostic imaging, Sarcoidosis physiopathology, Sarcoidosis diagnostic imaging, Coronary Circulation, Cardiomyopathies physiopathology, Cardiomyopathies diagnostic imaging, Positron Emission Tomography Computed Tomography
- Abstract
Purpose of the Review: Cardiac involvement in systemic sarcoidosis or isolated cardiac sarcoidosis plays a pivotal role in the clinical manifestation and prognostication. Active-inflammatory cardiac sarcoidosis is associated with a regional impairment of coronary microvascular function that may confer further detrimental effects on myocardial function needing further characterization., Recent Findings: Clinical investigations with cardiac positron emission tomography/computed tomography in conjunction with
18 F-fluorodeoxyglucose to determine myocardial inflammation and13 N-ammonia to quantify myocardial blood flow (MBF) in patients with known or suspected cardiac sarcoidosis outlined that sarcoidosis-induced myocardial inflammation was associated with adverse effects on corresponding regional coronary microvascular function. Notably, immune-suppressive treatment caused reductions in myocardial inflammation were paralleled by improvements of coronary microvascular dysfunction outlining direct adverse effect of inflammation on coronary arteriolar function. This review summarizes contributions of cardiac PET imaging in the identification and characterization of active-inflammatory cardiac sarcoidosis, its effect on coronary microvascular function, treatment responses, and prognostic implications., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
45. A Comparison of the Association of Septal Scar Burden on Responses to LBBAP-CRT and BVP-CRT.
- Author
-
Chen Z, Ma X, Wu S, Gao Y, Song Y, Lu M, Dai Y, Zhang S, Hua W, Gold MR, Zhao S, and Chen K
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Heart Septum diagnostic imaging, Heart Septum physiopathology, Echocardiography, Cardiomyopathies physiopathology, Cardiomyopathies therapy, Cardiomyopathies complications, Bundle-Branch Block physiopathology, Bundle-Branch Block therapy, Treatment Outcome, Stroke Volume physiology, Ventricular Remodeling physiology, Heart Failure physiopathology, Heart Failure therapy, Cicatrix physiopathology, Cicatrix diagnostic imaging, Cardiac Resynchronization Therapy
- Abstract
Background: Left bundle branch area pacing (LBBAP) is an alternative to biventricular pacing (BVP) for cardiac resynchronization therapy (CRT). However, despite the presence of left bundle branch block, whether cardiac substrate may influence the effect between the 2 strategies is unclear., Objectives: This study aims to assess the association of septal scar on reverse remodeling and clinical outcomes of LBBAP compared with BVP., Methods: We analyzed patients with nonischemic cardiomyopathy who had CRT indications undergoing preprocedure cardiac magnetic resonance examination. Changes in left ventricular ejection fraction (LVEF) and echocardiographic response (ER) (≥5% absolute LVEF increase) were assessed at 6 months. The clinical outcome was the composite of all-cause mortality, heart failure hospitalization, or major ventricular arrhythmia., Results: There were 147 patients included (51 LBBAP and 96 BVP). Among patients with low septal scar burden (below median 5.7%, range: 0% to 5.3%), LVEF improvement was higher in the LBBAP than the BVP group (17.5% ± 10.9% vs 12.3% ± 11.8%; P = 0.037), with more than 3-fold increased odds of ER (OR: 4.35; P = 0.033). In high sepal scar subgroups (≥5.7%, range: 5.7%-65.9%), BVP trended towards higher LVEF improvement (9.2% ± 9.4% vs 6.4% ± 12.4%; P = 0.085). Interaction between septal scar burden and pacing strategy was significant for ER (P = 0.002) and LVEF improvement (P = 0.011) after propensity score adjustment. During median follow-up of 33.7 (Q1-Q3: 19.8-42.1) months, the composite clinical outcome occurred in 34.7% (n = 51) of patients. The high-burden subgroups had worse clinical outcomes independent of CRT method., Conclusions: Remodeling response to LBBAP and BVP among nonischemic cardiomyopathy patients is modified by septal scar burden. High septal scar burden was associated with poor clinical prognosis independent of CRT methods., Competing Interests: Funding Support and Author Disclosures This work was supported by the National Natural Science Foundation of China (Grant Number 81870260), High-level Hospital construction project of Fuwai Hospital (Grant Number 2022-GSP-GG-31), and CAMS Innovation Fund for Medical Sciences (CIFMS) (Grant Number 2022-I2M-C&T-B-049). Dr Gold has received consulting fees from Boston Scientific, EBR, and Medtronic; and has received clinical trial support from Boston Scientific and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Cardiac manifestations in inherited metabolic diseases.
- Author
-
Cuenca-Gómez JÁ, Lara-Rojas CM, and Bonilla-López A
- Subjects
- Humans, Cardiomyopathies etiology, Cardiomyopathies diagnosis, Cardiomyopathies physiopathology, Metabolism, Inborn Errors diagnosis, Metabolism, Inborn Errors complications, Heart Diseases etiology, Heart Diseases diagnosis, Heart Diseases physiopathology
- Abstract
Inherited metabolic diseases (IMD) are caused by the functional defect of an enzyme, of genetic origin, that provokes a blockage in a specific metabolic pathway. Individually, IMD are considered rare diseases, with an incidence of less than 1/100,000 births. The symptoms are usually multisystemic, but frequently include cardiac manifestations. Of these, the most common are cardiomyopathies, especially hypertrophic cardiomyopathy. In addition, they can cause dilated or restrictive cardiomyopathy and non-compacted cardiomyopathy of the left ventricle. Characteristic signs also include rhythm alterations (atrio-ventricular conduction disturbances, Wolff-Parkinson-White syndrome or ventricular arrhythmias), valvular pathology and ischaemic coronary pathologies. The aim of this study is to present a narrative review of the IMD that may produce cardiac involvement. We describe both the specific cardiac manifestations of each disease and the systemic symptoms that guide diagnosis., Competing Interests: Declaration of competing interest The authors declare they have no conflicts of interest regarding this study., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Pathophysiology of Cardiac Amyloidosis.
- Author
-
Morfino P, Aimo A, Franzini M, Vergaro G, Castiglione V, Panichella G, Limongelli G, and Emdin M
- Subjects
- Humans, Heart Failure physiopathology, Heart Failure metabolism, Oxidative Stress, Myocardium pathology, Myocardium metabolism, Amyloidosis physiopathology, Amyloidosis metabolism, Cardiomyopathies physiopathology, Cardiomyopathies metabolism
- Abstract
Amyloidosis refers to a heterogeneous group of disorders sharing common pathophysiological mechanisms characterized by the extracellular accumulation of fibrillar deposits consisting of the aggregation of misfolded proteins. Cardiac amyloidosis (CA), usually caused by deposition of misfolded transthyretin or immunoglobulin light chains, is an increasingly recognized cause of heart failure burdened by a poor prognosis. CA manifests with a restrictive cardiomyopathy which progressively leads to biventricular thickening, diastolic and then systolic dysfunction, arrhythmias, and valvular disease. The pathophysiology of CA is multifactorial and includes increased oxidative stress, mitochondrial damage, apoptosis, impaired metabolism, and modifications of intracellular calcium balance., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
48. Pyruvate Kinase M2: A Potential Regulator of Cardiac Injury Through Glycolytic and Non-glycolytic Pathways.
- Author
-
Zeng C, Wu J, and Li J
- Subjects
- Animals, Humans, Energy Metabolism, Cell Proliferation, Regeneration, Cardiomyopathies enzymology, Cardiomyopathies pathology, Cardiomyopathies metabolism, Cardiomyopathies genetics, Cardiomyopathies physiopathology, Pyruvate Kinase metabolism, Pyruvate Kinase genetics, Glycolysis, Myocytes, Cardiac enzymology, Myocytes, Cardiac pathology, Myocytes, Cardiac metabolism, Signal Transduction, Fibrosis
- Abstract
Abstract: Adult animals are unable to regenerate heart cells due to postnatal cardiomyocyte cycle arrest, leading to higher mortality rates in cardiomyopathy. However, reprogramming of energy metabolism in cardiomyocytes provides a new perspective on the contribution of glycolysis to repair, regeneration, and fibrosis after cardiac injury. Pyruvate kinase (PK) is a key enzyme in the glycolysis process. This review focuses on the glycolysis function of PKM2, although PKM1 and PKM2 both play significant roles in the process after cardiac injury. PKM2 exists in both low-activity dimer and high-activity tetramer forms. PKM2 dimers promote aerobic glycolysis but have low catalytic activity, leading to the accumulation of glycolytic intermediates. These intermediates enter the pentose phosphate pathway to promote cardiomyocyte proliferation and heart regeneration. Additionally, they activate adenosine triphosphate (ATP)-sensitive K + (K ATP ) channels, protecting the heart against ischemic damage. PKM2 tetramers function similar to PKM1 in glycolysis, promoting pyruvate oxidation and subsequently ATP generation to protect the heart from ischemic damage. They also activate KDM5 through the accumulation of αKG, thereby promoting cardiomyocyte proliferation and cardiac regeneration. Apart from glycolysis, PKM2 interacts with transcription factors like Jmjd4, RAC1, β-catenin, and hypoxia-inducible factor (HIF)-1α, playing various roles in homeostasis maintenance, remodeling, survival regulation, and neovascularization promotion. However, PKM2 has also been implicated in promoting cardiac fibrosis through mechanisms like sirtuin (SIRT) 3 deletion, TG2 expression enhancement, and activation of transforming growth factor-β1 (TGF-β1)/Smad2/3 and Jak2/Stat3 signals. Overall, PKM2 shows promising potential as a therapeutic target for promoting cardiomyocyte proliferation and cardiac regeneration and addressing cardiac fibrosis after injury., Competing Interests: The authors report no conflicts of interest., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
49. Demonstration of Arrhythmia Substrate-Associated Dispersion of Repolarization by Epicardial Unipolar Mapping in Brugada Syndrome.
- Author
-
Nagase S, Kataoka N, Morita H, Kamakura T, Ueoka A, Nakamura T, Oka S, Miyazaki Y, Wakamiya A, Nakajima K, Ueda N, Wada M, Ishibashi K, Inoue Y, Miyamoto K, Aiba T, and Kusano K
- Subjects
- Humans, Male, Middle Aged, Female, Adult, Electrophysiologic Techniques, Cardiac methods, Aged, Cardiomyopathies physiopathology, Brugada Syndrome physiopathology, Epicardial Mapping, Electrocardiography
- Abstract
Background: Epicardial unipolar mapping has not been thoroughly investigated in Brugada syndrome (BrS)., Objectives: This study aims to examine the characteristics of epicardial unipolar potentials in BrS and investigate the differences from overt cardiomyopathy., Methods: Epicardial mapping was performed in 8 patients with BrS and 6 patients with cardiomyopathy. We investigated the J-wave amplitudes using unipolar recordings at delayed potential (DP) sites via bipolar recordings. The repolarization time (RT) at and around the DP recording sites was measured, and maximum dispersion of the RT divided by the distance was defined as the RT dispersion index., Results: Epicardial mapping at baseline revealed significantly higher J-wave amplitude with bipolar DP in patients with BrS than in patients with cardiomyopathy. J-wave amplitude ≥0.42 mV had 99.1% sensitivity and 100% specificity for diagnosing BrS. The RT dispersion index was significantly higher in patients with BrS than in patients with cardiomyopathy at baseline. In all patients with BrS, coved-type unipolar electrograms without negative T waves (short RT) appeared close to coved-type electrograms with negative T waves (long RT) at the DP recording sites after pilsicainide administration. Thus, a steep RT dispersion was observed in this region, and ventricular arrhythmias emerged from this shorter RT area in all 3 patients with BrS in whom ventricular arrhythmias were induced., Conclusions: Bipolar DP-related prominent unipolar J waves and steep repolarization gradients may be more specific for characterizing BrS than for overt cardiomyopathy. Ventricular arrhythmias in BrS are associated with a steep repolarization gradient, indicating phase 2 re-entry as a possible cause., Competing Interests: Funding Support and Author Disclosures Drs Nagase and Morita are affiliated with departments that receive grants from Medtronic. Dr Kataoka has received grants from Medtronic; and has received speaker fees from Medtronic, Biosense Webster, and Abbott. Drs Kamakura, Wakamiya , and Nakajima have received speaker fees from Medtronic and Biosense Webster. Dr Ueda has received speaker fees from Medtronic. Dr Ishibashi has received speaker fees from Medtronic, Abbott, and Japan Lifeline. Dr Miyamoto has received grants from Medtronic, Biosense Webster, and Abbott; and has received speaker fees from Medtronic, Biosense Webster, and Abbott. Dr Kusano has received grants from Medtronic, Biosense Webster, and Abbott; and has received speaker fees from Medtronic and Biosense Webster. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Non-dilated left ventricular non-compaction cardiomyopathy with systolic dysfunction is reclassified as non-dilated left ventricular cardiomyopathy with hypertrabeculation.
- Author
-
Miaris N
- Subjects
- Humans, Male, Female, Isolated Noncompaction of the Ventricular Myocardium complications, Isolated Noncompaction of the Ventricular Myocardium physiopathology, Isolated Noncompaction of the Ventricular Myocardium diagnostic imaging, Middle Aged, Cardiomyopathies complications, Cardiomyopathies physiopathology, Cardiomyopathies diagnostic imaging, Cardiomyopathies diagnosis, Systole, Ventricular Dysfunction, Left physiopathology, Ventricular Dysfunction, Left diagnostic imaging
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.